Massive Bio Recognized in Two Key Categories on CB Insights’ AI Drug Research & Development Market Map

CHICAGO--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights’ latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio’s innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions.

CB Insights’ market map highlights companies at the forefront of leveraging AI to accelerate drug discovery and development. Massive Bio’s inclusion in both the “Clinical Trial Matching” and “Patient Recruitment” categories reflects its dual impact on streamlining clinical trial processes and enhancing patient access to cutting-edge therapies.

“Being recognized by CB Insights in two critical categories is a testament to our team’s dedication to transforming oncology care,” said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. “Our AI-driven platform is designed to bridge the gap between patients and clinical trials, ensuring that individuals receive the most appropriate and timely treatments available.”

Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer, added, “This acknowledgment validates our commitment to integrating advanced AI technologies into clinical workflows. By optimizing trial matching and patient recruitment, we’re not only improving operational efficiencies but also enhancing patient outcomes in oncology.”

This recognition from CB Insights follows a milestone presence at ASCO25, where Arturo Loaiza-Bonilla presented a poster session on AI-powered clinical trial matching and participated in the ASCO/ESMO Joint Session, emphasizing international collaboration in oncology innovation. In addition, Selin Kurnaz was named a PCC Wayfinder, honoring her leadership in advancing equitable access and data-driven transformation in cancer care.

Massive Bio’s platform utilizes sophisticated algorithms and real-time data analytics to match cancer patients with suitable clinical trials, considering factors such as genetic profiles, treatment histories, and geographic locations. This approach has significantly increased trial enrollment rates and reduced the time required to identify eligible participants.

The company’s dual recognition by CB Insights highlights its comprehensive approach to addressing challenges in clinical trial enrollment and patient engagement. As the demand for personalized cancer treatments grows, Massive Bio continues to lead in providing scalable, AI-driven solutions that connect patients with life-saving clinical trials.

About Massive Bio

Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit www.massivebio.com.